Stockscreener 앱 받기
3.81
1.33%
0.05
시간 외 거래:
3.81
전일 마감가:
$3.76
열려 있는:
$3.79
하루 거래량:
53,914
Relative Volume:
1.83
시가총액:
$38.59M
수익:
$52.16M
순이익/손실:
$-48.60M
주가수익비율:
-4.1868
EPS:
-0.91
순현금흐름:
$-77.48M
1주 성능:
+2.14%
1개월 성능:
-5.93%
6개월 성능:
-59.04%
1년 성능:
-17.32%
1일 변동 폭
$3.73
$4.0247
1주일 범위
$3.72
$4.11
52주 변동 폭
$3.4145
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
명칭
Hookipa Pharma Inc
전화
0114318906360
주소
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-11-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | 개시 | Morgan Stanley | Overweight |
| 2020-11-03 | 개시 | Truist | Buy |
| 2020-10-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-19 | 재개 | H.C. Wainwright | Buy |
| 2019-09-27 | 개시 | H.C. Wainwright | Buy |
| 2019-05-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-13 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Hookipa Pharma Inc 주식(HOOK)의 최신 뉴스
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com South Africa
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
HOOKIPA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade - Yahoo Canada Finance
HOOK (HOOKIPA Pharma) Market Cap : $51.06 Mil (As of Aug. 02, 2024) - GuruFocus.com
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in July - MarketBeat
Hookipa Pharma (NASDAQ:HOOK) versus AC Immune (NASDAQ:ACIU) Critical Comparison - Defense World
Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00 - Defense World
Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00 at JMP Securities - MarketBeat
Q2 2024 EPS Estimates for Hookipa Pharma Inc (NASDAQ:HOOK) Lifted by Analyst - MarketBeat
Hookipa Pharma Announces Executive Reshuffle and Board Enhancements - TipRanks
Hookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Earn Q2 2024 Earnings of ($1.48) Per Share - Defense World
HOOKIPA Pharma appoints new CEO and CFO, reviews strategy - Investing.com India
HOOKIPA Pharma Appoints Dr. Malte Peters as CEO - citybiz
HOOKIPA Pharma Announces Director Dr. Malte Peters Named CEO And Director Terry Coelho Named Executive Vice President And CFO - Quantisnow
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 - GlobeNewswire
Hookipa Pharma Inc (HOOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):